216 related articles for article (PubMed ID: 16635070)
41. Cold storage of pooled, buffy-coat-derived, leucoreduced platelets in plasma.
Hornsey VS; Drummond O; McMillan L; Morrison A; Morrison L; MacGregor IR; Prowse CV
Vox Sang; 2008 Jul; 95(1):26-32. PubMed ID: 18393944
[TBL] [Abstract][Full Text] [Related]
42. Interruption of agitation of platelet concentrates: a multicenter in vitro study by the BEST Collaborative on the effects of shipping platelets.
Dumont LJ; Gulliksson H; van der Meer PF; Murphy S; Nixon JG; de Wildt-Eggen J; Vandenbroeke T; Aubuchon JP
Transfusion; 2007 Sep; 47(9):1666-73. PubMed ID: 17725732
[TBL] [Abstract][Full Text] [Related]
43. Reevaluation of the resting time period when preparing whole blood-derived platelet concentrates with the platelet-rich plasma method.
Moroff G; Kline L; Dabay M; Hunter S; Johnson A; McNeil D; Nixon J; Sawyer S; Taylor H; Whitley P; Wahab F; Murphy S
Transfusion; 2006 Apr; 46(4):572-7. PubMed ID: 16584433
[TBL] [Abstract][Full Text] [Related]
44. The effect of interruption of agitation on in vitro measures of platelet concentrates in additive solution.
van der Meer PF; Liefting LA; Pietersz RN
Transfusion; 2007 Jun; 47(6):955-9. PubMed ID: 17524082
[TBL] [Abstract][Full Text] [Related]
45. Interruption of agitation of platelet concentrates: effects on in vitro parameters.
van der Meer PF; Gulliksson H; Aubuchon JP; Prowse C; Richter E; de Wildt-Eggen J;
Vox Sang; 2005 May; 88(4):227-34. PubMed ID: 15877643
[TBL] [Abstract][Full Text] [Related]
46. Comparison of the in vitro properties of apheresis platelets during 7-day storage after interrupting agitation for one or three periods.
Wagner SJ; Vassallo R; Skripchenko A; Einarson M; Seetharaman S; Moroff G
Transfusion; 2008 Dec; 48(12):2492-500. PubMed ID: 18764829
[TBL] [Abstract][Full Text] [Related]
47. Markers of platelet activation and apoptosis in platelet concentrates collected by apheresis.
Procházková R; Andrýs C; Hubácková L; Krejsek J
Transfus Apher Sci; 2007 Oct; 37(2):115-23. PubMed ID: 17945536
[TBL] [Abstract][Full Text] [Related]
48. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience.
Lachert E; Kubis J; Antoniewicz-Papis J; Rosiek A; Woźniak J; Piotrowski D; Przybylska Z; Mikołowska A; Marschner S; Łętowska M
Adv Clin Exp Med; 2018 Jun; 27(6):765-772. PubMed ID: 29877637
[TBL] [Abstract][Full Text] [Related]
49. In vitro assays used in the evaluation of the quality of stored platelets: correlation with in vivo assays.
Holme S
Transfus Apher Sci; 2008 Oct; 39(2):161-5. PubMed ID: 18760673
[TBL] [Abstract][Full Text] [Related]
50. Storage of platelet concentrates from pooled buffy coats made of fresh and overnight-stored whole blood processed on the novel Atreus 2C+ system: in vitro study.
Sandgren P; Callaert M; Shanwell A; Gulliksson H
Transfusion; 2008 Apr; 48(4):688-96. PubMed ID: 18194379
[TBL] [Abstract][Full Text] [Related]
51. New methods showing in vitro changes of platelets.
Rock G; Freedman M; Hamilton C; Bormanis J
Transfus Apher Sci; 2006 Oct; 35(2):145-9. PubMed ID: 17097924
[TBL] [Abstract][Full Text] [Related]
52. The use of riboflavin for the inactivation of pathogens in blood products.
Goodrich RP
Vox Sang; 2000; 78 Suppl 2():211-5. PubMed ID: 10938955
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.
Wagner SJ; Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Moroff G; Carmichael P; Lin L
Transfusion; 2009 Apr; 49(4):704-10. PubMed ID: 19171001
[TBL] [Abstract][Full Text] [Related]
54. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment.
Schubert P; Coupland D; Culibrk B; Goodrich RP; Devine DV
Transfusion; 2013 Dec; 53(12):3164-73. PubMed ID: 23521225
[TBL] [Abstract][Full Text] [Related]
55. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates.
Abonnenc M; Sonego G; Crettaz D; Aliotta A; Prudent M; Tissot JD; Lion N
Transfusion; 2015 Sep; 55(9):2219-30. PubMed ID: 25873361
[TBL] [Abstract][Full Text] [Related]
56. Overnight or fresh buffy coat-derived platelet concentrates prepared with various platelet pooling systems.
Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
Transfusion; 2008 Apr; 48(4):723-30. PubMed ID: 18208415
[TBL] [Abstract][Full Text] [Related]
57. In vivo recovery of human platelets in severe combined immunodeficient mice as a measure of platelet damage.
Piper JT; Gelderman MP; Vostal JG
Transfusion; 2007 Aug; 47(8):1540-9. PubMed ID: 17655600
[TBL] [Abstract][Full Text] [Related]
58. Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days.
Albanyan AM; Harrison P; Murphy MF
Transfusion; 2009 Jan; 49(1):108-17. PubMed ID: 18954396
[TBL] [Abstract][Full Text] [Related]
59. Platelet capacity of various platelet pooling systems for buffy coat-derived platelet concentrates.
Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
Transfusion; 2008 Oct; 48(10):2114-21. PubMed ID: 18647365
[TBL] [Abstract][Full Text] [Related]
60. Viability and function of 8-day-stored apheresis platelets.
Slichter SJ; Bolgiano D; Jones MK; Christoffel T; Corson J; Rose L; Foley J; Popovsky M; Baril LL; Corda T; Dincecco DM; Snyder EL
Transfusion; 2006 Oct; 46(10):1763-9. PubMed ID: 17002633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
